About Viamet Pharmaceuticals
Viamet Pharmaceuticals is a company based in Durham (United States) founded in 2005 by Thomas OHalloran was acquired by NovaQuest Capital Management in January 2018. Viamet Pharmaceuticals has raised $160.8 million across 9 funding rounds from investors including Woodford Investment Management, U.S. Department of Defense and Brandon Point Industries. The company has 22 employees as of December 31, 2020. Viamet Pharmaceuticals offers products and services including Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and Fescousa.com. Viamet Pharmaceuticals operates in a competitive market with competitors including Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Elion Therapeutics, among others.
- Headquarter Durham, United States
- Employees 22 as on 31 Dec, 2020
- Founders Thomas OHalloran
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mycovia Pharmaceuticals (Nc), Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$160.8 M (USD)
in 9 rounds
-
Latest Funding Round
$12 M (USD), Series E
Sep 28, 2016
-
Investors
Woodford Investment Management
& 8 more
-
Employee Count
22
as on Dec 31, 2020
-
Acquired by
NovaQuest Capital Management
(Jan 03, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Viamet Pharmaceuticals
Viamet Pharmaceuticals offers a comprehensive portfolio of products and services, including Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and Fescousa.com.
Offers AI training to empower healthcare professionals for work and profit.
Provides online courses for skill development and education.
Delivers strategies for wealth-building and business acumen.
Offers fire safety consulting and training solutions.
Provides leading fire protection and emergency services.
Manages lodging and logistics for nuclear energy operations.
Advances satellite networks for global communications.
Delivers AI-driven content creation and copying tools.
Offers AI resources for enhancing business skills.
Funding Insights of Viamet Pharmaceuticals
Viamet Pharmaceuticals has successfully raised a total of $160.8M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $12 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Viamet Pharmaceuticals
Viamet Pharmaceuticals has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Woodford Investment Management, U.S. Department of Defense and Brandon Point Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
Early-stage life sciences investments are targeted in the healthcare sector.
|
Locked | Locked | Locked |
Investor details for Viamet Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Viamet Pharmaceuticals
Investment portfolio details for Viamet Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Viamet Pharmaceuticals
Detailed financials for Viamet Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viamet Pharmaceuticals Comparisons
Peer comparison for Viamet Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Viamet Pharmaceuticals
Viamet Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Elion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| Locked | Locked | Locked |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| Locked | Locked | Locked |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment.
|
Detailed competitors of Viamet Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viamet Pharmaceuticals
Complete news archive for Viamet Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viamet Pharmaceuticals
Viamet Pharmaceuticals was founded in 2005.
Viamet Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Viamet Pharmaceuticals is a funded company, having raised a total of $160.8M across 9 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Viamet Pharmaceuticals is 22.
Viamet Pharmaceuticals was founded in 2005 in Durham, United States, within the biotechnology sector. Small molecule inhibitors of metalloenzymes are identified through the Metallophile platform to address chronic and life-threatening fungal infections. The lead candidate, VT-1161, is advanced in Phase 2b trials for recurrent vulvovaginal candidiasis and onychomycosis. Preclinical efforts include VT-1129 for cryptococcal meningitis and VT-1598 for invasive fungal infections.
Viamet Pharmaceuticals's top competitors include Scynexis, F2g and Amplyx Pharmaceuticals.
Viamet Pharmaceuticals offers Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and 5 more products and services.
Viamet Pharmaceuticals has 9 investors. Key investors include Woodford Investment Management, U.S. Department of Defense, Brandon Point Industries, Novartis Venture Fund, and Lilly Ventures.